L'intérêt à découvert pour Mitsubishi donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Mitsubishi. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Mitsubishi (OTC:MTSUY) Stock, Rapport sur les intérêts à découvert

Mitsubishi Corp is a conglomerate that operates businesses in various industries. Its operating segments include Natural Gas, Industrial materials, Petroleum & chemicals, Mineral resource, Industrial Infrastructure, Automotive, Food & Consumer Industry, Power Solution, and Urban Development.

MITSUBISHI CORP UNSP ADR by Mitsubishi Corp.

Mitsubishi Corp

Fractyl Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will present a poster of new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois.
Poster Presentation Details
Session Title: Late Breaking Poster Session Abstract Title: Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice Poster Number: 1970-LB Date and Time: Sunday, June 22, 2025, 12:30 p.m. – 1:30 p.m. Location: Poster Hall (Hall F1, Level 3)

News

GUTS

Fractyl Health To Present Poster Of New Preclinical Data From Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform At ADA 85th Scientific Sessions

MoneyHero (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNY#NASDAQ">MNY</a>) reported quarterly losses of $(0.10) per share. This is a 66.67 percent increase over losses of $(0.30) per share from the same period last year. The company reported $14.31 million in sales this quarter. This is a 35.45 percent decrease over sales of $22.18 million the same period last year.

Earnings

MoneyHero Q1 EPS $(0.10) Up From $(0.30) YoY, Sales $14.31M Down From $22.18M YoY

JP Morgan analyst Andrea Teixeira upgrades Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) from Neutral to Overweight and raises the price target from $6 to $7.

Upgrades

Price Target

Analyst Ratings

JP Morgan Upgrades Newell Brands to Overweight, Raises Price Target to $7

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma –
– In combination with small molecule inhibitors, ARV-393 demonstrated enhanced tumor growth inhibition, including tumor regressions, in models of aggressive diffuse large B-cell lymphoma (DLBCL) –
NEW HAVEN, Conn., June 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI also known as AITL) and PDX models of transformed follicular lymphoma (tFL). In combination with oral small molecule inhibitors (SMIs), ARV-393 demonstrated enhanced antitumor activity, including tumor regressions, in cell line-derived xenograft (CDX) models of high-grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL). The results from these preclinical studies were shared at the European Hematology Association (EHA) 2025 Congress in Milan, Italy.
Key findings from the preclinical studies included:
<ul>
<li>Single-agent ARV-393 significantly reduced tumor burden in peripheral blood, bone marrow and spleen in a systemic PDX model of nTFHL-AI derived from a patient who relapsed post chemotherapy. This is potentially the first preclinical evidence of anti-tumor activity with an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model.</li>
<li>ARV-393 monotherapy treatment resulted in robust (≥95%) tumor growth inhibition (TGI) in two PDX models of tFL.</li>
<li>ARV-393 in combination with 5 classes of SMIs targeting potentially cooperative oncogenic drivers (tazemetostat, palbociclib, everolimus, acalabrutinib, or venetoclax) demonstrated increased TGI in CDX models of HGBCL and aggressive DLBCL compared with the respective monotherapy treatments. Tumor regressions were observed when ARV-393 was combined with tazemetostat, palbociclib, acalabrutinib, or venetoclax.</li>
<li>RNA sequencing studies carried out to further characterize downstream mechanism of action suggested that ARV-393 inhibits tumor cell cycle progression and promotes differentiation, driving antitumor activity and broad combinability in preclinical models.</li>
</ul>

ARVN

Arvinas Presents Data From Preclinical Studies Of ARV-393, PROTAC B-Cell Lymphoma 6 Protein Degrader, At EHA 2025 Congress

Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>, HKEX: 9688))) today announced new data from its preclinical study of ZL-1503, the Company's promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The findings, featured during a poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, Scotland, highlight the potential of ZL-1503 as a novel treatment option for moderate-to-severe AD.
Medications that inhibit IL-4/IL-13 signaling have markedly improved the therapeutic landscape for AD. Certain AD symptoms are mediated by IL-31; however, they are only partially alleviated by IL-4/IL-13 inhibition. As a result, many patients experience slow and modest clinical responses to currently available medications.
ZL-1503 was evaluated in a pilot preclinical study in non-human primates to assess its long-term effects on IL-31-mediated scratching and IL-13-induced signaling (pSTAT6). Key study results presented at the EAACI Congress 2025 include:
<ul>
<li>An intravenous single dose of ZL-1503 (10 mg/kg, iv) completely inhibited IL-13-mediated pSTAT6 and IL-31-induced scratching for at least 76 days in all preclinical subjects.</li>
<li>Two out of three subjects exhibited prolonged IL-13-mediated pSTAT6 inhibition for over 118 days, and one out of three subjects sustained IL-31-induced scratching inhibition for over 133 days.</li>
<li>Pharmacokinetic (PK) analysis of serum samples collected during the study revealed that ZL-1503 exhibited slow clearance, correlating closely pharmacodynamic (PD) responses, demonstrating strong PK/PD relationships in blocking IL-13 and IL-31 pathways in the preclinical model.</li>
<li>ZL-1503 was well tolerated following weekly IV dosing up to 150 mg/kg.</li>
<li>Additionally, in vitro studies showed that binding to one target did not affect ZL-1503's blocking effects on the other target.</li>
</ul>

ZLAB

Zai Lab Unveils New Atopic Dermatitis Drug That Blocks Both Itch and Inflammation for Over 3 Months in Study

Jefferies analyst Andy Barish upgrades Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) from Underperform to Hold and raises the price target from $165 to $210.

Jefferies Upgrades Darden Restaurants to Hold, Raises Price Target to $210

-- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction --
-- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction –
-- Well-Tolerated with a Favorable Safety Profile --
-- All Patients Remain on Navenibart --
-- Long-Term Data are Highly Consistent with Previous Results and Support the Potential Market-Leading Profile of Navenibart, Administered 2 or 4 Times Per Year --
-- Phase 3 ALPHA-ORBIT Trial Underway and Enrolling Patients --
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.astriatx.com&amp;esheet=54273873&amp;newsitemid=20250613335891&amp;lan=en-US&amp;anchor=Astria+Therapeutics%2C+Inc.&amp;index=1&amp;md5=cfd69ef5c1086a0f09f9ca618962670e">Astria Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These results demonstrated robust overall reduction in the monthly attack rate (92% mean and 97% median). These results further support navenibart's favorable safety and tolerability profile, and potential every three- (Q3M) and every six-month (Q6M) dosing regimens.

ATXS

Astria Therapeutics Reports Initial Results From Target Enrollment Group In Ongoing ALPHA-SOLAR Long-Term Open-Label Trial Evaluating Navenibart In HAE Patients

Citizens Financial Expands Share Buyback Authorization To $1.5B, Company Cites Confidence In Growth Outlook

Jefferies analyst Roger Song downgrades CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) from Buy to Hold and lowers the price target from $7 to $5.

Downgrades

CVAC

Jefferies Downgrades CureVac to Hold, Lowers Price Target to $5

The 2025 Global Gender Gap Index, released by the World Economic Forum, shows that gender parity worldwide is still a distant fantasy, with 68.8% of the gap closed across 148 economies, an improvement of only 0.3 percentage points from last year.
What Happened: At the current pace, the report says, it will take 123 years to achieve full global gender parity.
Iceland continues to lead with a 92.6% score, holding the top spot for 16 years and remaining the only country above the 90% mark. The top 10 economies, which have achieved 80% parity, are dominated by European nations, including Finland, Norway, Sweden, Germany and Ireland.
The Health and Survival (96.2%) and Educational Attainment (95.1%) gaps are nearly closed. However, Economic Participation (61%) and Political Empowerment (22.9%) still lag far behind.
Political Empowerment has seen the most long-term improvement, increasing by 9 percentage points since 2006, but full parity is still 162 years away. Economic Participation has improved by 5.6 points in the same period, with 135 years to go at the current rate.
Regionally, Northern America leads in 2025 with 75.8% overall parity and ranks first in economic participation. However, its economic gender gap has barely improved since 2006.
See Also: <a href="https://www.benzinga.com/news/topics/25/06/45858225/track-star-shacarri-richardson-partners-with-reddit-co-founder-alexis-ohanian-to-build-multicity-athlos-track-empire">Track Star Sha&#8217;Carri Richardson Partners With Reddit Co-Founder Alexis Ohanian To Build Multicity Athlos Track Empire</a>
Why It Matters: Closing the gender gap is projected to add up to $7 trillion to the global economy, UN Women estimates.
According to an OECD paper on gender equality and economic growth, "closing labour force participation gaps could add 0.10 p.p. of additional economic growth per year, culminating in a 3.9% boost to GDP per capita by 2060."
This WEF report, released every year, measures access and opportunities essential for reaching full economic potential. It offers a benchmark to inform policy decisions and business strategies.
Speaking <a href="https://www.livemint.com/news/indias-gender-gap-widens-as-it-drops-to-131st-spot-in-global-gender-gap-index-2025-11749710477982.html">to</a> the Press Trust of India, Saadia Zahidi, Managing Director, World Economic Forum, said: "At a time of heightened global economic uncertainty and a low growth outlook combined with technological and demographic change, advancing gender parity represents a key force for economic renewal."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45920453/trumps-student-loan-policies-could-inflict-massive-economic-harm-for-americans-warns-expert-instead-of-helping-the-5-million-borrowers">Trump&#8217;s Student Loan Policies Could Inflict &#8216;Massive Economic Harm,&#8217; For Americans, Warns Expert: &#8216;Instead Of Helping The 5 million Borrowers&#8230;&#8217;</a></li>
</ul>
Photo courtesy: Drop of Light / Shutterstock.com

World Economic Forum Says Gender Equality Is 123 Years Away: UN Projects $7 Trillion Boost To Global Economy If Gap Closes

Canaccord Genuity analyst George Gianarikas initiates coverage on USA Rare Earth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) with a Buy rating and announces Price Target of $17.

Initiation

USAR

Canaccord Genuity Initiates Coverage On USA Rare Earth with Buy Rating, Announces Price Target of $17

Recent federal procurement filings indicate that U.S. Immigration and Customs Enforcement (ICE) is ramping up its use of blockchain analytics technology to bolster efforts against illegal activity involving cryptocurrency.
What Happened: ICE issued notices of intent to purchase additional investigative tools from TRM Labs and Chainalysis, according to <a href="https://fedscoop.com/ice-wants-more-blockchain-analytics-tech/">a</a> Fedscoop report.
These companies are among the leading providers of blockchain forensics software. The agency shared that it plans to sole-source from both companies due to a lack of feasible alternatives for their specialized services.
Additional purchases from Magnet Forensics and Volexity are also in the pipeline. These companies are already known vendors across federal law enforcement agencies like the FBI and IRS.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45919840/trump-says-i-like-tesla-as-feud-with-elon-musk-subsides-but-i-also-like-combustion-engines">Trump Says &#8216;I Like Tesla&#8217; As Feud With Elon Musk Subsides: &#8216;But I Also Like Combustion Engines&#8217;</a>
Why It Matters: Blockchain transactions are visible on public ledgers, but they often obscure user identities. As criminal organizations continue to adopt digital currencies to evade detection, analytics platforms are becoming crucial for tracing hidden financial trails.
According to TRM Labs' Ari Redbord, these tools are aiding agencies to track cryptocurrency use in terrorism financing, human trafficking and cross-border smuggling. He highlighted that their systems can trace transactions even when bad actors use complex tactics to disguise activity.
ICE is stepping up its implementation of advanced technology across a variety of domains. Earlier this year, it signed a $29.8 million contract with Peter Thiel, the co-founder of Palantir Technologies Inc. (PLTR), to enhance its immigration enforcement tools.
The agency is currently making headlines for triggering <a href="https://www.benzinga.com/news/politics/25/06/45900294/trump-deploys-marines-to-la-with-authority-to-detain-civilians-california-challenges-military-involvement-in-immigration-enforcement">widespread protests</a> in Los Angeles against its <a href="https://www.benzinga.com/markets/equities/25/06/45854643/home-depot-targeted-in-immigration-raids-amid-la-protests-threatening-customer-traffic">targeted immigration raids</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45920411/trumps-approval-rating-hits-second-term-low-amid-ukraine-and-israel-conflicts">Trump&#8217;s Approval Rating Hits Second-Term Low Amid Ukraine And Israel Conflicts</a></li>
</ul>
Photo courtesy: chrisdorney / Shutterstock.com

Politics

PLTR

ICE Looks To Ramp Up Blockchain Surveillance Capabilities With New Purchases From TRM Labs, Chainalysis: Report

Keybanc analyst Steve Barger upgrades Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) from Sector Weight to Overweight and announces $21 price target.

Keybanc Upgrades Myers Indus to Overweight, Announces $21 Price Target

In response to Israel&#8217;s recent strikes on Iranian nuclear sites, President Donald Trump issued a stern warning to Iran, urging the country to negotiate or face dire consequences.
What Happened: Trump, via his Truth Social account on Friday, criticized Iran for failing to secure a nuclear deal despite multiple opportunities. He highlighted the military prowess of the U.S. and Israel, emphasizing their advanced weaponry and preparedness.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="606" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13063653/image-218.png" alt="" class="wp-image-948795" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13063653/image-218.png 606w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13063653/image-218-300x262.png 300w" sizes="(max-width: 606px) 100vw, 606px" /></figure>
Trump, referring to Israel&#8217;s &#8220;Rising Lion&#8221; strikes that damaged Natanz and eliminated Revolutionary Guard leaders, including Chief Hossein Salami, warned of severe repercussions.&nbsp;He stated that Iranian hardliners, now &#8220;all DEAD,&#8221; had underestimated the response. &nbsp;Trump urged Iran to swiftly engage in negotiations to prevent further &#8220;slaughter&#8221; and &#8220;brutal&#8221; planned attacks, cautioning of the potential collapse of the &#8220;Iranian Empire.&#8221;
The President&#8217;s post corresponds with reports of rising tensions in the Middle East and the cancellation of U.S.-Iran talks. His message, while advocating for diplomacy, also threatens the use of overwhelming force, sparking fears of a broader conflict in the region.
SEE ALSO:&nbsp;<a href="https://benzinga.com/crypto/25/06/45897204/gamestop-themed-crypto-skyrockets-over-500-after-retailer-announces-1-75-billion-investment-plan" target="_blank" rel="noreferrer noopener">GameStop-Themed Crypto Skyrockets Over 500% After Retailer Announces $1.75 Billion Investment Plan &#8211; Benzinga</a>
Why It Matters: The Trump administration had&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/45919250/trump-administration-distances-us-from-israels-strikes-on-iran-we-are-not-involved-says-marco-rubio">distanced itself </a>from Israel&#8217;s recent military actions against Iran, a move that was expected to complicate Trump&#8217;s efforts to negotiate a nuclear deal with Tehran. The U.S. was preparing for another round of talks on Iran&#8217;s uranium enrichment program, scheduled for Sunday.
Earlier, Trump had made a significant diplomatic gesture towards Iran, expressing hope for improved relations in the Middle East. This came as he lauded the transformative efforts of Saudi Arabia, Qatar, and the United Arab Emirates in turning their capitals into thriving commercial centers. Trump&#8217;s softer tone towards Iran was seen as an indication of his administration&#8217;s&nbsp;willingness to seek a <a href="https://www.benzinga.com/25/05/45395894/trump-makes-peace-gesture-at-iran-amid-middle-east-optimism-willing-to-end-past-conflicts-and-forge-new-partnerships">nuclear deal</a> with Tehran.
The recent events have had a significant impact on the markets, with U.S. stocks likely to open lower following Israel&#8217;s strikes on Iran. The geopolitical risks have also offered an upside for the dollar, raising concerns about a further rise in tensions in the Middle East and their impact on supply routes.
Meanwhile, defense stocks like Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), and General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) <a href="https://www.benzinga.com/markets/equities/25/06/45921574/lockheed-martin-rtx-general-dynamics-and-other-defense-stocks-rise-in-friday-pre-market-whats-going-on">climbed higher </a>in Friday&#8217;s pre-market trading session amid escalating tensions in the Middle East.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/tech/25/06/45920468/barack-obama-once-told-airbnb-ceo-brian-chesky-not-to-lead-like-a-self-driving-car-heres-what-former" target="_blank" rel="noreferrer noopener">Barack Obama Once Told Airbnb CEO Brian Chesky Not To Lead Like A &#8216;Self-Driving Car:&#8217; Here&#8217;s What Former President Meant</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Trump Issues Stark Warning To Iran To 'Make A Deal' After Israel's Strikes On Nuclear Sites: 'Just Do It Before It's Too Late'

IONR

Trading Halt: Halt status updated at 6:55:00 AM ET: Quotation Resumption: News and Resumption Times

Needham analyst Mike Matson reiterates Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) with a Buy and maintains $48 price target.

Reiteration

ESTA

Needham Reiterates Buy on Establishment Labs Hldgs, Maintains $48 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $73 price target.

Telsey Advisory Group Maintains Outperform on Kroger, Maintains $73 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Outperform and maintains $255 price target.

Telsey Advisory Group Maintains Outperform on RH, Maintains $255 Price Target

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Buy and maintains $35 price target.

Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $35 Price Target

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1)
 &nbsp;

Merck & Company Says FDA Has Approved KEYTRUDA (pembrolizumab) For PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma As Neoadjuvant Treatment, Continued As Adjuvant Treatment Combined With Radiotherapy With Or Without Cisplatin Then As A Single Agent

Comments

Mitsubishi

Intérêt court

Mitsubishi (OTC:MTSUY) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL